Study of children with eosinophilic gut disorders
Part of Blood & lymphatic, Digestive system, Immune system & allergy clinical trials.
This study looks at children ages 0–18 with eosinophilic gut disorders (EGIDs) to better understand these conditions and how they are managed. It may help doctors improve care by comparing real-world information from patients followed at participating hospitals.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be a child or teen age 0 to 18 years
- Have a diagnosis of eosinophilic gut disorder (EGID) at a participating center
- Have a signed consent form from a parent or legal guardian
- If the child is older than 6, also have the child sign consent
- Your EGID diagnosis must be made within the last 5 years
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study builds a registry of children with eosinophilic gastrointestinal (gut) disorders (EGIDs) and also includes children being evaluated for possible EGIDs. It may help doctors better understand these conditions and improve future care.
This study looks at how eosinophilic inflammation in the esophagus and intestines affects outcomes like symptoms and test findings. It may help clinicians better understand these conditions and track what changes over time.
This study looks at how inflamed the esophagus is in children who have eosinophilic esophagitis (EoE). It may help doctors better understand what’s driving symptoms like trouble swallowing and food getting stuck.
This study looks at how often children with eosinophilic esophagitis (a type of food allergy causing esophagus swelling) have immediate symptoms after eating certain foods. It may help doctors better understand and manage the condition.
This trial tests an intervention meant to improve how well adults with eosinophilic esophagitis (EoE) follow their ongoing treatment plan. It may help you stay on your medicine and get better symptom control by making adherence easier.
This Phase 1/2 study tests EP-104GI in adults with eosinophilic esophagitis (EoE), a condition where certain immune cells cause inflammation in the food pipe. It may help improve symptoms and inflammation, and the study also includes a part where people who do well can switch to the active drug.
Hear when a new Eosinophilic Gastrointestinal Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.